Market Place
Sourcing Support
Aytu BioPharma Disclosure Notification
03 Dec 2024 //
ACCESSWIRE
Aytu Bio Ranked One of Fastest-Growing Companies in North America
22 Nov 2024 //
ACCESSWIRE
Aytu BioPharma Reports Q1 FY 2025 Financial Results
13 Nov 2024 //
ACCESSWIRE
Aytu BioPharma to Report Fiscal 2025 Q1 Results on November 13
06 Nov 2024 //
ACCESSWIRE
Aytu Bio to Participate in the 2024 Maxim Healthcare Virtual Summit
14 Oct 2024 //
ACCESSWIRE
Aytu Partners With Lupin To Commercialize ADHD Drugs In Canada
01 Oct 2024 //
ACCESSWIRE
Aytu BioPharma To Report Fiscal 2024 Results
19 Sep 2024 //
ACCESSWIRE
Aytu BioPharma To Participate In Sidoti Micro-Cap Virtual Conference
08 Aug 2024 //
ACCESSWIRE
Aytu BioPharma Sells Consumer Health Business After Wind Down
06 Aug 2024 //
ACCESSWIRE
Aytu BioPharma Announces Paydown And Refinancing Of Term Loan On Favorable Terms
18 Jun 2024 //
ACCESSWIRE
Aytu Biopharma Lytham Participation: Spring 2024 Investor Conference
23 May 2024 //
ACCESSWIRE
Aytu BioPharma Reports Fiscal Q3 2024 Operational & Financial Results
15 May 2024 //
ACCESSWIRE
Aytu BioPharma To Report Q3 FY2024 Results On May 15
08 May 2024 //
ACCESSWIRE
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
03 Apr 2024 //
ACCESSWIRE
Aytu Reports Record ADHD Revenue During Fiscal 2024 Second Quarter
14 Feb 2024 //
ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial Results
07 Feb 2024 //
ACCESSWIRE
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
14 Nov 2023 //
ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results
07 Nov 2023 //
ACCESSWIRE
Aytu Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer
26 Oct 2023 //
ACCESSWIRE
Aytu to Present at Lytham Partners Fall 2023 Conference on October 17, 2023
09 Oct 2023 //
ACCESSWIRE
Aytu BioPharma Reports Record Revenues, Record Prescriptions
27 Sep 2023 //
ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results
21 Sep 2023 //
ACCESSWIRE
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
13 Sep 2023 //
ACCESSWIRE
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma
31 Jul 2023 //
ACCESSWIRE
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
14 Jun 2023 //
ACCESSWIRE
Aytu Bio Announces Closing of $4.0 Million Public Offering Priced At-the-Market
13 Jun 2023 //
ACCESSWIRE
Aytu Announces Pricing of $4.0 Million Public Offering Priced At-The-Market
09 Jun 2023 //
ACCESSWIRE
Aytu to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
04 May 2023 //
ACCESSWIRE
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
01 May 2023 //
ACESSWIRE
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
21 Feb 2023 //
ACCESSWIRE
Aytu Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
14 Feb 2023 //
ACCESSWIRE
Aytu to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
07 Feb 2023 //
ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
26 Jan 2023 //
ACCESSWIRE
Aytu to Present at Lytham Partners Investor Select Conference on January 31
24 Jan 2023 //
ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions
30 Nov 2022 //
ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance
22 Nov 2022 //
ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America
17 Nov 2022 //
ACCESSWIRE
Aytu Announces the Passing of Co-Founder and Board Member Michael Macaluso
16 Nov 2022 //
ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue & +ve Adjusted EBITDA in 1Q 2023
14 Nov 2022 //
ACCESSWIRE
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund
25 Oct 2022 //
ACCESSWIRE
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations
13 Oct 2022 //
ACCESSWIRE
Aytu BioPharma Announces Continuing Availability of ADHD Med Adzenys XR-ODT®
05 Oct 2022 //
ACCESSWIRE
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
28 Sep 2022 //
ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 FR Sep 27, 2022
20 Sep 2022 //
ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
16 Aug 2022 //
ACCESSWIRE
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
15 Aug 2022 //
ACCESSWIRE
Aytu BioPharma Announces Pricing of Public Offering
09 Aug 2022 //
ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for VEDS
20 Jul 2022 //
ACCESSWIRE
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated
25 Apr 2022 //
ACCESSWIRE
Aytu BioPharma Announces FTD Granted to AR101 for Ehlers-Danlos Syndrome
19 Apr 2022 //
ACCESSWIRE
Aytu BioPharma Announces Business & Pipeline Progress, Reports Q2 2022 Results
14 Feb 2022 //
ACCESSWIRE
Denovo Biopharma Announces Partner Aytu BioPharma Receives FDA Clearance
14 Dec 2021 //
BENZINGA
FDA Approves & Grants ODD to Aytu`s Enzastaurin in VEDS
14 Dec 2021 //
PRNEWSWIRE
Aytu BioPharma Announces Formation of New Scientific Advisory Board
09 Sep 2021 //
BIOSPACE
